Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04503577
NCT04503577
Recruiting
Not Applicable

Prospective Bladder Cancer Infrastructure: an Infrastructure for Observational and Interventional Bladder Cancer Research (ProBCI)

Prospective Bladder Cancer Infrastructure Foundation23 sites in 1 country3,600 target enrollmentOctober 4, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBladder Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bladder Cancer
Sponsor
Prospective Bladder Cancer Infrastructure Foundation
Enrollment
3600
Locations
23
Primary Endpoint
Overall survival
Status
Recruiting
Last Updated
8 months ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands

Registry
clinicaltrials.gov
Start Date
October 4, 2020
End Date
December 31, 2041
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Prospective Bladder Cancer Infrastructure Foundation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Bladder cancer
  • •Any stage except Ta
  • •18 years or older
  • •Written informed consent

Exclusion Criteria

  • •No exclusion criteria
  • •Note: participation in ProBCI does not exclude the patient from participation in other studies.

Outcomes

Primary Outcomes

Overall survival

Time Frame: 10 years

Alive/death/emigrated

Secondary Outcomes

  • Health-related quality of life(2 years)
  • Cancer-specific health-related quality of life(2 years)
  • Progression-free survival(10 yeas)
  • Recurrence-free survival(10 yeas)

Study Sites (23)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Prospective Bladder Cancer Infrastructure - An infrastructure for observational and interventional bladder cancer researchbladder cancer10038364
NL-OMON54621Stichting Prospectieve Blaaskanker Infrastructuur3,500
Recruiting
Not Applicable
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer PatientsBladder CancerQuality of Life
NCT05739968National Taiwan University Hospital120
Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-DESanochemia Pharmazeutika AG220
Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-ATSanochemia Pharmazeutika AG220
Completed
Phase 2
Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy(Hypericin PDD)C67Malignant neoplasm of bladder
DRKS00003324Sanochemia Pharmazeutika AG227